EMA Committee Refuses Licence for Alzheimer’s Drug Aducanumab in EU
A key committee for the European Medicines Agency has recommended refusing an application by the pharmaceutical company Biogen for a licence for the Alzheimer’s drug aducanumab.
Read more...